Clinical Trial Update: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for TMC278 (rilpivirine) in HIV-1 infected patients who have not received antiretroviral therapy, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC278 (rilpivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Human Immunodeficiency Virus Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2013-10-28